166 related articles for article (PubMed ID: 1533782)
21. Treatment of invasive fungal infections in immunocompromised patients with fluconazole.
Esposito R; Uberti Foppa C; Cernuschi M
J Chemother; 1989 Jul; 1(4 Suppl):925-6. PubMed ID: 16312707
[No Abstract] [Full Text] [Related]
22. Management of mycoses in patients with hematologic disease and cancer -- review of the literature.
Ruhnke M; Maschmeyer G
Eur J Med Res; 2002 May; 7(5):227-35. PubMed ID: 12069913
[TBL] [Abstract][Full Text] [Related]
23. [Nosocomial fungal infections, analysis of 149 cases].
Liu ZY; Sheng RY; Li XL; Li TS; Wang AX
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):399-402. PubMed ID: 12820917
[TBL] [Abstract][Full Text] [Related]
24. [AIDS and mycoses].
Aravinskiĭ RA
Sov Med; 1990; (7):28-33. PubMed ID: 2251558
[No Abstract] [Full Text] [Related]
25. Current drug therapy of systemic mycoses: a review.
Yonga G
East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014
[TBL] [Abstract][Full Text] [Related]
26. Drug treatment of the systemic mycoses.
Newberry WM
Semin Drug Treat; 1972; 2(3):313-29. PubMed ID: 4617926
[No Abstract] [Full Text] [Related]
27. In vivo models: evaluating antifungal agents.
Dixon DM
Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):729-38. PubMed ID: 3448452
[TBL] [Abstract][Full Text] [Related]
28. [Systemic mycotic infections].
Meunier F
Recenti Prog Med; 1990 Jan; 81(1):18-22. PubMed ID: 2173078
[TBL] [Abstract][Full Text] [Related]
29. Fungal infections in iatrogenically compromised hosts.
Rex JH; Walsh TJ; Anaissie EJ
Adv Intern Med; 1998; 43():321-71. PubMed ID: 9506187
[No Abstract] [Full Text] [Related]
30. [Commonly used antifungal agents in the treatment of systemic mycoses].
Berenguer Berenguer J
Rev Clin Esp; 1995 Oct; 195 Suppl 3():58-65. PubMed ID: 9441308
[No Abstract] [Full Text] [Related]
31. Fungal infection overview.
Treat Rev; 1995 May; (no 18):10. PubMed ID: 11362589
[TBL] [Abstract][Full Text] [Related]
32. [The treatment of aspergillosis, cryptococcosis and histoplasmosis in immunocompromised patients. Report of experience in the United States].
Hostetler JS; Stevens DA
Med Klin (Munich); 1991 Dec; 86 Suppl 1():8-10. PubMed ID: 1663205
[TBL] [Abstract][Full Text] [Related]
33. [Therapy of invasive organ mycoses in patients with systemic hematologic diseases].
Karthaus M; Böhme A
Wien Med Wochenschr; 2001; 151(3-4):80-8. PubMed ID: 11789423
[TBL] [Abstract][Full Text] [Related]
34. [Treatment with fluconazole of severe fungal infections in immunocompromised patients].
Boulos M
Rev Inst Med Trop Sao Paulo; 1993; 35(1):81-7. PubMed ID: 8278747
[TBL] [Abstract][Full Text] [Related]
35. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
Viscoli C; Castagnola E
Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
[TBL] [Abstract][Full Text] [Related]
36. [Mycoses as opportunistic infections in AIDS patients].
Viviani MA
Med Klin (Munich); 1991 Dec; 86 Suppl 1():19-22. PubMed ID: 1663202
[TBL] [Abstract][Full Text] [Related]
37. Approaches to management of fungal infections in cancer patients.
Francis P; Walsh TJ
Oncology (Williston Park); 1992 May; 6(5):133-44; discussion 144, 147-8. PubMed ID: 1534671
[TBL] [Abstract][Full Text] [Related]
38. Mucosal and invasive fungal infections in HIV/AIDS.
Hage CA; Goldman M; Wheat LJ
Eur J Med Res; 2002 May; 7(5):236-41. PubMed ID: 12069914
[TBL] [Abstract][Full Text] [Related]
39. [New aspects in treatment of systemic mycoses].
Presterl E; Graninger W
Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965
[TBL] [Abstract][Full Text] [Related]
40. Itraconazole: managing mycotic complications in immunocompromised patients.
Graybill JR
Semin Oncol; 1998 Jun; 25(3 Suppl 7):58-63. PubMed ID: 9671333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
